Bioqual, Inc.

**BIOQUAL offers animal models and services specific to COVID-19 research. Submit a quote request containing the word ‘COVID-19’ to receive more details.**

BIOQUAL was established in 1981, and performs contract research services focused on in vivo models of human diseases including AIDS, influenza, RSV infection, Flavivirus infections including Zika and Dengue, malaria, hepatitis, and cancer. BIOQUAL has laboratories and vivariums under both BSL-2 and BSL-3 containment. In addition, BIOQUAL maintains CDC-approved BSL-3 containment laboratories for studies associated with Select Agents including highly pathogenic avian influenza. BIOQUAL currently employs 160 personnel. Facilities: BIOQUAL, Inc. (Rockville, Maryland) has over 90,000 sq ft of dedicated BSL-2+ laboratory animal space and over 7,000 sq ft of laboratory space. Currently the laboratories are involved with SIV/SHIV and other viral disease of humans. Laboratories outfitted for molecular biology, special procedures and instrumentation are shared with other groups within the company. All laboratories are equipped with Class II, Type B laminar flow hoods, low speed centrifuges, dual chamber tissue culture incubators and refrigerator/freezers. Care and husbandry of all research animals will be provided in compliance with US federal laws and guidelines as well as in accordance with recommendations provided in the NIH guide and other accepted standards of laboratory animal care and use. BIOQUAL’s laboratories are actively involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. In vitro services are available for evaluation of immunologic, virologic, and molecular parameters. These services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.